21 completed, 6 recruiting, 5 active not recruiting, 4 unknown. 40 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 40 | Completed 21, Recruiting 6, Active not recruiting 5, Unknown 4, Terminated 3, Withdrawn 1 |
| Phase 2 | 4 | Completed 3, Terminated 1 |
Follow Disease Progression: new trials by email Literature Review of Disease Progression trials Research Report on Disease Progression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer FOLFOXIRI, CAPOX, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) - Locally Advanced Rectal Carcinoma | Phase 3 | Recruiting | J. W. A. Burger | 394 | 2026-03-16 | 2026-10-27 |
| Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment Capivasertib - Breast Cancer, HR-positive Breast Cancer | Phase 3 | Recruiting | Women's Cancer Study Group GmbH | 250 | 2025-11-27 | 2026-08-05 |
| 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma Cisplatin-based induction chemotherapy, Full course of PD-1 monoclonal antibody, Reduced-dose radiotherapy to CTV2 - Nasopharyngeal Carcinoma | Phase 3 | Recruiting | Ming-Yuan Chen | 346 | 2025-11-20 | 2026-01-09 |
| Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy Full course of PD-1blockades, Cisplatin-based induction chemotherapy, Standard-dose radiotherapy - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Recruiting | Ming-Yuan Chen | 456 | 2025-11-18 | 2026-01-09 |
| Omitting CTV for Primary Tumor in LS-SCLC Radiation Therapy, Etoposide + carboplatin; Etoposide + cisplatin, Creating CTV for primary tumor - SCLC, Limited Stage, Radiation Exposure | Phase 3 | Recruiting | Sun Yat-sen University | 852 | 2025-06-03 | 2025-06-06 |
| Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients Capivasertib, Fulvestrant - Breast Cancer | Phase 3 | Active not recruiting | AstraZeneca | 293 | 2024-09-26 | 2026-08-17 |
| Impact Of Metformin In Rectal Cancer Patients Metformin - Rectal Cancer Patients | Phase 2 / Phase 3 | Completed | Minia University | 85 | 2024-05-01 | 2025-08-01 |
| Propionic Acid in Multiple Sclerosis Propionic acid 1000 mg capsule, Placebo - Multiple Sclerosis | Phase 2 / Phase 3 | Completed | Salzburger Landeskliniken | 101 | 2024-05-01 | 2026-09-15 |
| A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002) T-Guard, Ruxolitinib - Steroid-Refractory Acute Graft Versus Host Disease | Phase 3 | Terminated | Xenikos | 12 | 2022-06-16 | 2024-08-27 |
| A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer Docetaxel + Carboplatin + Trastuzumab + Pertuzumab, (Epirubicin + Cyclophosphamide - Docetaxel) + (Trastuzumab + Pertuzumab) - Breast Cancer, HER2-positive Breast Cancer | Phase 3 | Withdrawn | Henan Cancer Hospital | 2022-05-11 | 2024-02-26 | |
| Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease Ferric Citrate 1 GM Oral Tablet [AURYXIA], Placebo - Anemia, Iron Deficiency, Hyperphosphatemia | Phase 3 | Completed | USRC Kidney Research | 289 | 2022-03-30 | 2025-08-29 |
| Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Tivozanib, Nivolumab - Renal Cell Carcinoma | Phase 3 | Completed | AVEO Pharmaceuticals, Inc. | 343 | 2021-09-09 | 2026-05-08 |
| Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients Cyclophosphamide 50mg, Methotrexate - Acute Lymphoblastic Leukemia (ALL) in Complete Remission, Acute Myeloid Leukemia (AML) in Remission | Phase 3 | Recruiting | King Faisal Specialist Hospital & Research Center | 264 | 2021-08-15 | 2025-03-13 |
| Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 Galinpepimut-S, Azacitidine, Venetoclax - Acute Myeloid Leukemia | Phase 3 | Active not recruiting | Sellas Life Sciences Group | 127 | 2021-02-08 | 2025-10-01 |
| Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression HCQ - Covid19, Progression | Phase 3 | Completed | UNICEF | 540 | 2020-04-10 | 2020-08-21 |
| NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab, epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab - Breast Cancer, Triple Negative Breast Neoplasms | Phase 3 | Active not recruiting | Lund University Hospital | 325 | 2019-12-20 | 2025-09-12 |
| A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy Rucaparib, Nivolumab, Placebo Oral Tablet - Epithelial Ovarian Cancer, Primary Peritoneal | Phase 3 | Active not recruiting | pharmaand GmbH | 1097 | 2018-05-14 | 2025-06-24 |
| Beginning of Effective and Safe Treatment in Immunoglobulin A-1 Nephropathy-1 Losartan group, Placebo group - Glomerulonephritis, Immunoglobulin A (IgA) | Phase 3 | Unknown | Ewha Womans University | 174 | 2018-01-30 | 2017-11-30 |
| Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III Temozolomide, Bevacizumab - Glioblastoma, Recurrence | Phase 3 | Completed | Kyorin University | 146 | 2016-07-11 | 2026-08-07 |
| Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT) Lenalidomide - Multiple Myeloma | Phase 3 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 273 | 2015-03-01 | 2020-05-11 |
Showing 20 of 40. Sign in to see all of them.
Pathologic Complete Response (18) · Breast Neoplasms (5) · Multiple Myeloma (5) · HIV Infections (4) · Leukemia, Myeloid, Acute (3) · Acquired Immunodeficiency Syndrome (2) · Hematologic Diseases (2) · Nasopharyngeal Carcinoma (2) · Ovarian Neoplasms (2) · Recurrence (2) · Renal Insufficiency, Chronic (2) · Anemia, Iron-Deficiency (1) · COVID-19 (1) · Carcinoma, Ovarian Epithelial (1)
Disease Attributes (40) · Pathologic Processes (40) · Pathological Conditions, Signs and Symptoms (40) · Neoplasms (23) · Neoplasms by Histologic Type (15) · Neoplasms by Site (13) · Urogenital Diseases (13) · Immune System Diseases (12) · Hemic and Lymphatic Diseases (11) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Hematologic Diseases (8) · Genital Diseases (7) · Immunoproliferative Disorders (7)
Bortezomib (3) · Carboplatin (3) · Cyclophosphamide (3) · Docetaxel (3) · Epirubicin (3) · Lenalidomide (3) · Azacitidine (2) · Capecitabine (2) · Cisplatin (2) · Dexamethasone (2) · Fluorouracil (2) · Leucovorin (2) · Nivolumab (2) · Oxaliplatin (2) · Radiotherapy (2)
Assistance Publique - Hôpitaux de Paris (2) · AstraZeneca (2) · Ming-Yuan Chen (2) · National Heart, Lung, and Blood Institute (NHLBI) (2) · 307 Hospital of PLA (1) · AGO Study Group (1) · AVEO Pharmaceuticals, Inc. (1) · Barts & The London NHS Trust (1) · Boehringer Ingelheim (1) · Celgene (1) · Ewha Womans University (1) · Fundación de Ayuda a la Investigación sobre la Hipertensión, Riesgo Cardiovascular y Enfermedades Renales (1) · Harvard School of Public Health (HSPH) (1) · Heidelberg University (1) · Henan Cancer Hospital (1)
United States (12) · France (10) · Germany (10) · Italy (8) · Spain (8) · China (7) · Poland (7) · United Kingdom (7) · Belgium (6) · Australia (5) · Canada (5) · Portugal (5) · Brazil (4) · Czechia (4) · Israel (4)
Mary Horowitz, MD (2) · Michele Cavo, MD (2) · Ming-Yuan Chen, MD,PhD (2) · David R Boulware, MD, MPH (1) · Donald Abrams, MD (1) · Dong-Ryeol Ryu, Professor (1) · Fatma M Mady, professor (1) · Franz Schaefer, MD (1) · Geoff Block, MD (1) · Jacobus Pfisterer, Prof. Dr. med. (1) · Jacobus WA Burger, Prof. dr. (1)
PMID 14630977, PMID 14744931, PMID 15206062, PMID 15253732, PMID 15647341, PMID 15772249, PMID 16093916, PMID 16966687, PMID 19828532, PMID 20812949, PMID 20844049, PMID 21146205, PMID 22498745, PMID 22911697, PMID 23073950, PMID 23194056, PMID 23592699, PMID 23636235, PMID 23897961, PMID 24028546, PMID 24870935, PMID 25562355, PMID 26908541, PMID 27432930, PMID 27776843, PMID 27829371, PMID 28379796, PMID 29943364, PMID 30345884, PMID 30385039, PMID 30653422, PMID 30982686, PMID 31639132, PMID 31645472, PMID 32090636, PMID 32621487, PMID 32687451, PMID 33006656, PMID 33151787, PMID 33242443, PMID 33369355, PMID 33862001, PMID 34454540, PMID 34593565, PMID 34643690, PMID 34715071, PMID 34995344, PMID 35170751, PMID 35224730, PMID 35230699
2009 (2), U01HL069294 (2), 2005 (1), 2017 (1), 2025 (1), U01AI046957 (1), U10HL069294 (1), U24HL138660 (1)